Cytokine Storm Implicates Use of Baricitinib in Hospitalized amCOVID-19 Patients

Time: 11:55 am
day: Day One


  • Narrating Lilly’s fast- approval process for Baracitinib for pandemic application
  • Addressing the MOA of a cytokine storm and effects this provides on JAKi use
  • Potential anti-host anti-viral mechanism for Baricitinib and potential implications